the Minium Alveolar Concentration (MAC)-awake of Sevoflurane in Patients with End-Stage Renal Disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-15007608

Enrollment

Unknown

Registered

2015-12-16

Start date

2016-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end-stage renal disease

Interventions

control:to investigate the MAC-awake of sevoflurane in patients with normal renal function

end-stage renal disease:to investigate the MAC-awake of sevoflurane in patients with end-stage renal disease

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with end-stage renal disease undergoing dialysis who are arranged for parathyroidectomy under general anesthesia and patients with American Society of Anesthesiology grade I or II who are arranged for general anesthesia.

Exclusion criteria

Exclusion criteria: Patient suffered psychosis or take the antipsychotics for a long time; the long-term use of sedative drug addicts; a history of cardiovascular, respiratory, or hepatic disease; acid-base disturbance, blood electrolyte dysfunction; a history of either alcohol or drug abuse; excitement with sevoflurane.

Design outcomes

Primary

Measure	Time frame
MAC-awake of sevoflurane;	—

Secondary

Measure	Time frame
renal function;neuron-specific enolase;S100B protein;MAP at base;HR at base;SpO2 at base;MAP at awakening the patient;HR at awakening the patient;SpO2 at awakening the patient;blood gas analysis at awakening the patient;	—

Countries

China

Contacts

Public ContactYe Zhang

zhangye_hassan@sina.com+86 13966768081

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026